Search results for "thromboembolic event"

showing 2 items of 2 documents

Effect of the Alterations in Contractility and Morphology Produced by Atrial Fibrillation on the Thrombosis Potential of the Left Atrial Appendage

2021

Atrial fibrillation (AF) is a common arrhythmia mainly affecting the elderly population, which can lead to serious complications such as stroke, ischaemic attack and vascular dementia. These problems are caused by thrombi which mostly originate in the left atrial appendage (LAA), a small muscular sac protruding from left atrium. The abnormal heart rhythm associated with AF results in alterations in the heart muscle contractions and in some reshaping of the cardiac chambers. This study aims to verify if and how these physiological changes can establish hemodynamic conditions in the LAA promoting thrombus formation, by means of computational fluid dynamic (CFD) analyses. In particular, sinus …

medicine.medical_specialtyHistologythromboembolic eventleft atrial appendagelcsh:Biotechnology0206 medical engineeringBiomedical EngineeringThrombogenicityHemodynamicsBioengineering02 engineering and technology030204 cardiovascular system & hematologyContractilitySettore ING-IND/14 - Progettazione Meccanica E Costruzione Di Macchine03 medical and health sciencescomputational fluid dynamic0302 clinical medicinecardiac wall motionInternal medicinelcsh:TP248.13-248.65Medicineatrial fibrillationThrombusStrokeOriginal ResearchFibrillationbusiness.industrySettore ING-IND/34 - Bioingegneria IndustrialeBioengineering and BiotechnologyAtrial fibrillationmedicine.disease020601 biomedical engineeringThrombosisCardiologymedicine.symptombusinessBiotechnologyFrontiers in Bioengineering and Biotechnology
researchProduct

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Mali…

2021

Immune checkpoint inhibitors (ICI) significantly improved the prognosis of advanced melanoma patients. However, many patients do not derive long-term benefit from ICI therapy due to primary and acquired resistance. In this regard, it has been shown that coagulation factors contribute to cancer immune evasion and might therefore promote resistance to ICI. In particular, recent observations in murine systems demonstrated that myeloid-derived factor Xa (FXa) impedes anti-tumor immunity in the tumor microenvironment and that the oral FXa inhibitor (FXa-i) rivaroxaban synergizes with ICI. The synergistic effect of FXa inhibitors with clinical ICI therapy is unknown. We performed a retrospective …

Oncologyadvanced melanomaCancer Researchmedicine.medical_specialtymedicine.drug_mechanism_of_actionmedicine.medical_treatmentFactor Xa Inhibitorfactor Xa inhibitorsanti-tumor immunityArticleimmune checkpoint inhibitorsInternal medicinemedicineProgression-free survivalanticoagulationRC254-282thromboembolic eventsRivaroxabanbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerRetrospective cohort studyImmunotherapymedicine.diseaseOncologyConcomitantimmunotherapythromboprophylaxisbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugCohort studyCancers
researchProduct